

World Journal of Advanced Research and Reviews

eISSN: 2581-9615 CODEN (USA): WJARAI Cross Ref DOI: 10.30574/wjarr Journal homepage: https://wjarr.com/



(RESEARCH ARTICLE)



Post recovery symptoms and complication corresponding COVID-19 infection

Wasfi Dhahir Abid ali, Mahfoud Falih Hasan, Semahir S, Hameed and luay abdulwahid shihab *

Department of Basic Science, College of Nursing, University of Basrah. Iraq.

World Journal of Advanced Research and Reviews, 2022, 14(03), 146-155

Publication history: Received on 04 April 2022; revised on 14 May 2022; accepted on 17 May 2022

Article DOI: https://doi.org/10.30574/wjarr.2022.14.3.0417

Abstract

This study was conducted on those recovering from infection with the COVID_19 virus and aims to assess the pathological complications after recovery. A Google electronic form was used to collect data from male and female participants. The results showed that there was a significant correlation between sex and severity of infection with the complications of the disease after recovery, especially joint pain, fatigue and hair loss. The results did not show significant differences for the correlation coefficient between the variables and other complications of the disease.

Keywords: Complication; COVID-9; Symptoms; Infection

1. Introduction

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019. The disease has since spread worldwide, leading to an ongoing pandemic. [1]. Symptoms of COVID-19 are variable, but often include fever, cough, headache, fatigue, breathing difficulties, and loss of smell and taste. Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms [2, 3, 4].

COVID-19 transmits when people breathe in air contaminated by droplets and small airborne particles containing the virus. The risk of breathing these in is highest when people are in close proximity, but they can be inhaled over longer distances, particularly indoors. Transmission can also occur if splashed or sprayed with contaminated fluids in the eyes, nose or mouth, and, rarely, via contaminated surfaces. People remain contagious for up to 20 days, and can spread the virus even if they do not develop symptoms. [5]. [2] Found that olfactory dysfunction has been observed as one of the clinical manifestations in COVID-19 patients [6, 7]. Handful of studies reported the observation of olfactory dysfunction in COVID-19 patients. Following that the Ear, Nose, and Throat [8]. Limited evidence suggests that ACE 2 expression is attenuated in females compared with the males which could justify the higher number of COVID-19 cases in men [9, 10]. [11] Stated that the mortality rate of COVID-19 increases by up to 49% in patients who develop ARDS. Age, neutrophilia, elevated LDH and D-dimer are the identified risk factors for the development of ARDS; Similar to the MERS, a positive association of neutrophilia and lung damage has been recognized in COVID-19 [12]. A study include 243 patients suggests that AST elevation occurs in 20% of the COVID-19 patients (95% CI: 15.3-25.6%). In addition from six studies including 197 patients indicates that ALT elevation is observed in 14.6% of COVID-19 cases (95% CI: 12.8-16.6%) [13]. other reports indicate that in 14-53% of COVID-19 cases, abnormal levels of aminotransferases (AST and ALT) are observed [14]. Teachers are the main caregivers and the first line of protection for school children. Their role complements that of parents. During school hours, school teachers are actually the first-respondent in cases of disasters or emergencies. They must be able to deal properly with health emergencies both in normal children, and those children with special health care needs [19]. Healthcare professionals have realized that much of their technical and

^{*} Corresponding author: luay abdulwahid shihab Department of Basic Science, College of Nursing, University of Basrah. Iraq.

administrative activities arrelated to the management and provision of patient information, diagnosis, treatment and medical research. Hence, we can recognize the role of computer and the idea of using it in medicine and its relation to health sciences and the relationship of the latter with computer science and medical engineering [20].

2. Material and methods

The current study included forty people who participated in answering the questionnaire prepared in Google format and included demographic information that included age, gender, injury severity and recovery from injury. With or without treatment and information related to the most important complications of the disease after recovery from infection with the COVID-19 virus, including Body pain, Joints pain or headache, High blood sugar (hyperglycemia), Fever, Fatigue, Feeling of tiredness or lack of energy ,Loss of taste or smell, Shortness of breath or difficulty breathing, Coughing or Chest pain, Hair loss and Inability to focus or difficulty thinking or a lack of mental clarity ,Difficulty in sleeping, Rapid or fast heartbeat ,Insomnia, anxiety disorder or depression ,Dizziness or lightheaded when you stand up from sitting or lying down Red bumps or rash on a flat, red patch of skin , and symptoms that get worse after mental or physical activities. The data were analyzed using the Statistical Package for Social Sciences (SPSS), version 26. Include Percentage (%) and Chi square (X²).

3. Results and discussion

Symptoms, signs, or abnormal clinical parameters persisting two or more weeks after COVID-19 onset that do not return to a healthy baseline can potentially be considered long-term effects of the disease (15).

Table 1 Distribution of the Variables Related Demographic Characteristics N=40 patients

Descriptive statistic	cs of Demographic Va	riable	es
Demographic Variables	Variables Classes	F	Percent
Sex	Male	21	52.5 %
	Female	19	47.5 %
	Total	40	100 %
	18-35	18	45 %
Age	36-60	22	55 %
Age	Total	40	100 %
	10-30 %	28	70 %
Severity of infection	40-60 %	8	20 %
	More 60 %	4	10 %
	Total	40	100 %
Recovery	Without treatment	18	45 %
	With treatment	22	55 %
	Total	40	100.0

Table (1) showed that there were no differences in percentage regarding gender or age but the severity of infection were more between 10-30%.on other hand there were no differences corresponding with or without treatment.

The percentage of period of complication in table (2) sowed that most participants suffer some time from post recovery complication Body pain, Joints pain or headache and Insomnia, anxiety disorder or depression 57.5, Shortness of breath or difficulty breathing, Inability to focus or difficulty thinking or a lack of mental clarity 42%, Difficulty in sleeping and Rapid or fast heartbeat 45%, Dizziness or lightheaded when you stand up from sitting or lying down and Symptoms that get worse after mental or physical activities 47.5%.

The authors (16) performed a survey in a Facebook group of patients who previously had COVID-19 and compared the symptoms of those hospitalized with mild to moderate symptoms. They concluded that both groups had symptoms after 3 months of having COVID-19. (17) Found that Dyspnea and cough were found in 24% and 19% of patients, respectively In addition, abnormalities in CT lung scans persisted in 35% of patients even after 60–100 days from the initial presentation. Gandhi (18) Stated that Later in the disease, a hyper inflammatory state and coagulopathy are thought to lead to clinical complications; in this stage, anti-inflammatory medications.

Table 2 Results of symptoms for post complication of COVID-19 infection

	Frequencies and percentage for post complic	cation	of COVID-1	9 infe	ction		
No	Questions	No symptoms		Son	ne Time	A	lways
		F	%	F	%	F	%
1	Body pain, Joints pain or headache	8	20 %	23	57.5 %	9	22.5 %
2	High blood sugar (hyperglycemia)	36	90 %	3	7.5 %	1	2.5 %
3	Fever	14	35 %	18	45 %	8	20 %
4	Fatigue, Feeling of tiredness or lack of energy	5	12.5 %	14	35 %	21	52.5 %
5	Loss of taste or smell	15	37.5 %	11	27.5 %	14	35 %
6	Shortness of breath or difficulty breathing		45 %	17	42.5 %	5	12.5 %
7	Coughing or Chest pain		42.5 %	15	37.5 %	8	20 %
8	Hair loss	17	42.5 %	13	32.5 %	10	25 %
9	Inability to focus or difficulty thinking or a lack of mental clarity	12	30 %	17	42.5 %	11	27.5 %
10	Difficulty in sleeping	15	37.5 %	18	45 %	7	17.5 %
11	Rapid or fast heartbeat	16	40 %	18	45 %	6	15 %
12	Insomnia, anxiety disorder or depression	10	25 %	23	57.5 %	7	17.5 %
13	Dizziness or lightheaded when you stand up from sitting or lying down	13	32.5 %	19	47.5 %	8	20 %
14	Red bumps or rash on a flat, red patch of skin	34	85 %	4	10 %	2	5 %
15	Symptoms that get worse after mental or physical activities	21	52.5 %	19	47.5 %	0	0 %

Table 3 Comparison of symptoms (post complication of COVID-19 infection) according to gender

	Comparison of	symptoms between	en male a	and female	by chi sqı	ıare		
no	Questions	Symptoms		Sex			Significant	
			Male	Female	Total	X2	P - value	Sig
			N	N	N	7.58	0.023	S
	Body pain, Joints pain or headache	No Symptoms	1	7	8			
1		Some Time	13	10	23			
		Always	7	2	9			
		Total	21	19	40			
		No Symptoms	20	16	36	1.68	0.355	Ns

			I	1	1			
2	High blood sugar (hyperglycemia)	Some Time	1	2	3			
	(nypergrycenna)	Always	0	1	1			
		Total	21	19	40			
		No Symptoms	5	9	14	3.27	0.185	Ns
3	Fever	Some Time	10	8	18			
		Always	6	2	8			
		Total	21	19	40			
	Fatigue, Feeling of tiredness or	No Symptoms	1	4	5	2.89	0.220	Ns
4	lack of energy	Some Time	7	7	14			
		Always	13	8	21			
		Total	21	19	40			
		No Symptoms	7	8	15	0.78	0.672	Ns
5	Loss of taste or smell	Some Time	7	4	11			
		Always	7	7	14			
		Total	21	19	40			
	Shortness of breath or	No Symptoms	8	10	18	1.79	0.407	Ns
6	difficulty breathing	Some Time	11	6	17			
		Always	2	3	5			
		Total	21	19	40			
		No Symptoms	8	9	17	0.56	0.756	Ns
7	Coughing or Chest pain	Some Time	9	6	15			
		Always	4	4	8			
		Total	21	19	40			
		No Symptoms	3	14	17	17.7	0.00	S
8	Hair loss	Some Time	8	5	13			
		Always	10	0	10			
		Total	21	19	40			
	Inability to focus or difficulty	No Symptoms	3	9	12	7.43	0.024	S
9	thinking or a lack of mental clarity	Some Time	9	8	17			
	clarity	Always	9	2	11			
		Total	21	19	40			
		No Symptoms	5	10	15	3.75	0.153	Ns
10	Difficulty in sleeping	Some Time	11	7	18	1		
		Always	5	2	7	-		
		Total	21	19	40	1		
		No Symptoms	5	11	16	4.82	0.890	Ns
11	Rapid or fast heartbeat	Some Time	12	6	18			
		Always	4	2	6	1		

		Total	21	19	40			
	Insomnia, anxiety disorder or	No Symptoms	1	9	10	9.74	0.008	S
12	depression	Some Time	15	8	23			
		Always	5	2	7			
		Total	21	19	40			
	Dizziness or lightheaded when	No Symptoms	4	9	13	6.39	0.041	S
13	you stand up from sitting or lying down	Some Time	10	9	19			
	<i>y</i> 8 · ·	Always	7	1	8			
		Total	21	19	40			
	Red bumps or rash on a flat,	No Symptoms	16	18	34	4.02	0.133	Ns
14	red patch of skin	Some Time	4	0	4			
		Always	1	1	2			
		Total	21	19	40			
	Symptoms that get worse after	No Symptoms	9	12	21	1.54	0.199	Ns
15	mental or physical activities	Some Time	12	7	19			
		Always	0	0	0			
		Total	21	19	40			

^{*}Ns = Non significant, X^2 = chi square, degree of freedom = (columns – 1)* (rows – 1), P – value < 0.05 = significant(S) accept that non-significant (Ns).

Table 4 Comparison of symptoms (post complication of COVID-19 infection) according to Injury level

	Comparison of sympton	oms between 10-3	80 %, 40-6	0 %and 6	0-80% Inj	ury level	s by ch	i square	
				Injury	Significant				
no	Questions	Symptoms	10-30 %	40-60 %	60-80 %	Total	X2	P – value	Sig
			N	N	N	N			
		No Symptoms	6	1	1	8			
	Body pain, Joints pain	Some Time	16	5	2	23	0.42	0.98	Ns
1	or headache	Always	6	2	1	9			
		Total	28	8	4	40			
		No Symptoms	26	7	3	36			
	High blood sugar	Some Time	2	1	0	3	9.70	0.04	S
2	(hyperglycemia)	Always	0	0	1	1	7.70	0.04	3
		Total	28	8	4	40		0.04	
		No Symptoms	8	4	2	14			
		Some Time	16	1	1	18	5.98	0.20	Ns
3	Fever	Always	4	3	1	8	3.70	0.20	143
		Total	28	8	4	40			
-		No Symptoms	4	0	1	5			

4	Fatigue, Feeling of	Some Time	9	5	0	14	5.50	0.24	Ns
	tiredness or lack of	Always	15	3	3	21			
	energy	Total	28	8	4	40			
		No Symptoms	11	2	2	15			
		Some Time	8	3	0	11	2.26	0.68	Ns
5	Loss of taste or smell	Always	9	3	2	14	2.20	0.00	INS
		Total	28	8	4	40			
		No Symptoms	12	3	3	18			
	Shortness of breath	Some Time	14	3	0	17	5.18	0.28	Ns
6	or difficulty breathing	Always	2	2	1	5	3.10	0.20	INS
	J T	Total	28	8	4	40			I
		No Symptoms	13	2	2	17			
		Some Time	11	3	1	15	2.65	0.61	Na
7	Coughing or Chest pain	Always	4	3	1	8	2.65	0.61	Ns
	pam	Total	28	8	4	40			
		No Symptoms	12	2	3	17			
		Some Time	7	6	0	13	10.2	0.02	C
8	Hair loss	Always	9	0	1	10	10.3	0.03	S
		Total	28	8	4	40			
	Inability to focus or	No Symptoms	9	2	1	12	2.13		
		Some Time	10	5	2	17		0.71	Na
9	a lack of mental	Always	9	1	1	11	2.13		Ns
	clarity	Total	28	8	4	40			
		No Symptoms	11	3	1	15			
		Some Time	12	4	2	18	0.53	0.07	Ns
10	Difficulty in sleeping	Always	5	1	1	7	0.55	0.97	INS
		Total	28	8	4	40			•
		No Symptoms	10	3	3	16			
		Some Time	14	3	1	18	3.12	0.52	Ns
11	Rapid or fast heartbeat	Always	4	2	0	6	3.12	0.55	INS
		Total	28	8	4	40			•
		No Symptoms	9	1	0	10			
	Insomnia, anxiety	Some Time	14	6	3	23	2 22	0.53	NI
12	disorder or depression	Always	5	1	1	7	3.22	0.52	Ns
	,	Total	28	8	4	40			1
	Dizziness or	No Symptoms	9	3	1	13			
12	lightheaded when you stand up from	Some Time	11	5	3	19	4.07	0.20	N.
13	sitting or lying down	Always	8	0	0	8	4.97	0.97	Ns

		Total	28	8	4	40			
		No Symptoms	24	7	3	34			
Red bumps or rash on a flat, red patch of	Some Time	3	0	1	4	2.98	0.56	Ns	
14	skin	Always	1	1	0	2	2.70	0.50	143
14		Total	28	8	4	40			
		No Symptoms	17	2	2	21			
	Symptoms that get	Some Time	11	6	2	19	3.19	0.20	Ns
15	worse after mental or physical activities	Always	0	0	0	0	3.17	0.20	143
		Total	28	8	4	40			

^{*}Ns = Non-significant, X2 = chi square, degree of freedom = (columns - 1)* (rows - 1), P - value < 0.05 = significant(S) accept that non-significant (Ns).

Table 5 Comparison of symptoms (post complication of COVID-19 infection) according to Recovery

	Comparison of symptoms	between without	treatment and	with treatmer	ıt Recove	ry by cl	hi square		
]	Recovery		Significant			
no	Questions	Symptoms	Without treatment	With treatment	Total	X2	P – value	Sig	
			N	N	N				
		No Symptoms	6	2	8				
	Body pain, Joints pain or	Some Time	11	12	23	7.16	0.02	S	
1	headache	Always	1	8	9				
		Total	18	22	40				
		No Symptoms	17	19	36				
	High blood sugar	Some Time	1	2	3	1.05	0.59	Ns	
2	(hyperglycemia)	Always	0	1	1	1.03	0.39	113	
		Total	18	22	40				
		No Symptoms	9	5	14	5.52 0.63			
		Some Time	8	10	18		0.62	Ns	
3	Fever	Always	1	7	8	3.32	0.03	113	
		Total	18	22	40				
		No Symptoms	4	1	5				
	Fatigue, Feeling of tiredness or lack of	Some Time	8	6	14	5.59	0.061	Ns	
4	energy	Always	6	15	21	3.39	0.001	1113	
		Total	18	22	40				
		No Symptoms	9	6	15				
		Some Time	5	6	11	2.89	0.23	Ns	
5	Loss of taste or smell	Always	4	10	14	2.09	0.23	INS	
		Total	18	22	40				
		No Symptoms	12	6	18				
6	Shortness of breath or difficulty breathing	Some Time	6	11	17		0.01	S	
U	annearcy breathing	Always	0	5	5	0.13	0.01	3	

		Total	18	22	40			
		No Symptoms	10	7	17			
		Some Time	6	9	15	0.55	0.05	
7	Coughing or Chest pain	Always	2	6	8	2.75	0.25	Ns
		Total	18	22	40			I
		No Symptoms	10	7	17			
		Some Time	4	9	13	2.45	0.20	
8	Hair loss	Always	4	6	10	2.47	0.29	Ns
		Total	18	22	40			<u> </u>
		No Symptoms	7	5	12			
	Inability to focus or	Some Time	9	8	17	4.40	0.40	
9	difficulty thinking or a lack of mental clarity	Always	2	9	11	4.49	0.10	Ns
	inon or monour chartey	Total	18	22	40			1
		No Symptoms	10	5	15			
		Some Time	6	12	18	4.5	0.10	N.
10	Difficulty in sleeping	Always	2	5	7	4.5	0.10	Ns
		Total	18	22	40			1
		No Symptoms	10	6	16			
		Some Time	7	11	18	410	0.12	NI -
11	Rapid or fast heartbeat	Always	1	5	6	4.19	0.12	Ns
		Total	18	22	40			1
		No Symptoms	7	3	10			
	Insomnia, anxiety	Some Time	9	14	23	2.00	0.16	Na
12	disorder or depression	Always	2	5	7	3.60	0.25 0.29 0.10 0.10 0.12 0.69 0.09	Ns
		Total	18	22	40			
		No Symptoms	9	4	13			
	Dizziness or lightheaded	Some Time	4	15	19	0.47	0.01	C
13	when you stand up from sitting or lying down	Always	5	3	8	8.47	0.01	S
	0 , 0	Total	18	22	40		0.29 0.10 0.12 0.16 0.69	•
		No Symptoms	16	18	34			
	Red bumps or rash on a	Some Time	1	3	4	0.72	0.60	Na
14	flat, red patch of skin	Always	1	1	2	0.72	0.69	Ns
		Total	18	22	40			-
		No Symptoms	12	9	21			
	Symptoms that get	Some Time	6	13	19	262	0.09	Ns
15	worse after mental or physical activities	Always	18	22	40	2.63		INS
				+				

^{*}Ns = Non-significant, X2 = chi square, degree of freedom = (columns – 1)* (rows – 1), P – value < 0.05 = significant(S) accept that non-significant (Ns).

4. Conclusion

The present study concludes that many patients even they recovered COVID-19 infection they suffered from the post complication, especially muscular and joint pain, hair loss shortness of breath or difficulty breathing.

Compliance with ethical standards

Acknowledgments

Thanks, and appreciation to the College of Nursing, University of Basra.

Disclosure of conflict of interest

There are no conflicts of interest and all researchers are compatible.

Statement of informed consent

The present research work does not contain any studies performed on animals/humans subjects by any of the authors.

References

- [1] Zimmer,C;The Secret Life of a Coronavirus An oily, 100-nanometer-wide bubble of genes has killed more than two million people and reshaped the world. Scientists don't quite know what to make of it". Retrieved 28 February 2021.
- [2] Saniasiaya J, Islam MA. Prevalence of Olfactory Dysfunction in Coronavirus Disease 2019 (COVID-19): A Meta-analysis of 27,492 Patients. The Laryngoscope. April 2021; 131(4): 865878.
- [3] Saniasiaya J, Islam MA. Prevalence and Characteristics of Taste Disorders in Cases of COVID-19: A Meta-analysis of 29,349 Patients. Otolaryngology–Head and Neck Surgery. November 2020; 165 (1): 33–42.
- [4] Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. Mayo Clin Proc. August 2020; 95(8): 1621–1631.
- [5] CDC. Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention. 11 February 2020.
- [6] Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. Clin Infect Dis. 2020; 71: 889–890.
- [7] Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and ageusia: common 2ndings in COVID-19 patients. Laryngoscope. 2020; 130: 1787.
- [8] Xydakis MS, Dehgani-Mobaraki P, Holbrook EH, et al. Smell and taste dysfunction in patients with COVID-19. Lancet Infect Dis. 2020; 20(9): 1015–1016.
- [9] Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE 2, the receptor of SARS-CoV-2. Am. J.Resp. Crit. Care Med.
- [10] Dashraath P, Jeslyn WJL, Karen LMX et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am. J. Obstet. Gynecol. 2020; 222(6): 521–531.
- [11] Wu C, Chen X, Cai Y et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020; 180(7): 1–11.
- [12] Ng Dl, Hosani FA, Keating Mk et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014. Am. J. Pathol. 2016; 186(3): 652–658.
- [13] Parasa S, Desai M, Thoguluva Chandrasekar V et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with Coronavirus Disease 2019. JAMA Netw. Open. 2020; 3(6): E2011335.
- [14] Wong SH, Lui R, Sung JJ. Covid-19 and the digestive system. J. Gastroenterol. Hepatol. 2020; 35(5): 744–748.
- [15] Tenforde MW. et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March-June 2020. Morb. Mortal Wkly Rep. 69: 993–998.

- [16] Goertz YM. J. et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: The post-COVID-19 syndrome? ERJ Open Res. 2020.
- [17] Sandra Lopez-Leon, Talia Wegman-Ostrosky, Carol Perelman, Rosalinda Sepulveda Paulina A. Rebolledo, Angelica Cuapio & Sonia Villapol More than 50 long-term effects of COVID-19: a systematic review and meta-analysis Scientific Reports. 2021; 11: 16144.
- [18] Gandhi RT. The multidimensional challenge of treating COVID-19: remdesivir is a foot in the door. Clin Infect Dis. (Epub ahead of print). 31 July 2020.
- [19] Wasfi Dhahir Abid Ali, Luay Abdulwahid Shihab, Maryam Abdulkareem Abdulrazaq, Noor Sabah Daif, & Nabaamussab Hassan. Assessment of Teachers' Knowledge About First Aid Some Basrah City Schools, Best: International Journal of Humanities, Arts, Medicine and Sciences. 2021; 9(2): 7–12.
- [20] Luaay abdulwahid shihab, ISRAA HUSSIN ABD, Zeinab Faisal Abd, Zahia Abdel-Hussein Masatar, Evaluation of the nurses' knowledge about the internet, Journal of Network Computing and Applications. Clausius Scientific Press, Canad. 2018; 3: 1-7.